Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Inclusion Criteria: * Treatment-naive systemic ALK-positive ALCL patients * Histologically confirmed diagnosis of cluster of differentiation (CD)30-positive ALCL with documented ALK-positive status * Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and dimensional measurable disease of at least 1.5 cm as documented by radiographic technique (spiral computed tomography \[CT\] preferred) * Eastern Cooperative Oncology Group (ECOG) performance status =\< 3 * Absolute neutrophil count (ANC) \>= 1500/ul * Platelet count \>= 75,000/ul (unless documented bone marrow involvement with lymphoma) * Hemoglobin (Hgb) \>= 8 gr/dL * Serum creatinine =\< 1.5 x mg/dL and/or calculated creatinine clearance (using Cockcroft-Gault formula) \>= 30 mL/min * Total bilirubin =\< 1.5 x upper limit of normal (ULN), except for patients with Gilbert's syndrome or documented hepatic involvement with lymphoma who may be included if bilirubin =\< 3.0 x ULN or direct bilirubin =\< 1.5 x ULN * Aspartate transaminase (AST) =\< 3 x ULN, except with liver involvement by the lymphoma who are only included if AST =\< 5 x ULN; alanine transaminase (ALT) \< 3.0 x ULN, except with liver involvement by the lymphoma who are only included if AST =\< 5 x ULN * Alkaline phosphatase (ALP) =\< 5.0 x ULN * Fasting plasma glucose =\< 175 mg/dL (=\< 9.8 mmol/L) * Serum amylase =\< 2 x ULN * Serum lipase =\< ULN * Patients must have the following laboratory values or have the following laboratory va…